瑞巴派特三联疗法用于胃溃疡伴胃出血的临床观察

Clinical Observation of Rebamipide Triple Therapy in the Treatment of Gastric Ulcer with Bleeding

目的:观察瑞巴派特三联疗法用于胃溃疡伴胃出血的疗效和安全性。方法:130例胃溃疡伴胃出血患者随机分为对照组(65例)和观察组(65例)。对照组患者给予奥美拉唑肠溶胶囊20 mg,口服,每日2次+铝碳酸镁片500 mg,口服,每日1次;观察组患者在对照组治疗的基础上给予瑞巴派特片0.1 g,口服,每日3次。两组疗程均为12周。观察两组患者的临床疗效,嗳气、腹痛、腹胀、呕血/便血缓解时间,治疗前后临床症状评分,再出血发生情况及不良反应发生情况。结果:观察组患者近期总有效率显著高于对照组,临床症状与体征缓解时间均显著短于对照组,再出血发生率显著低于对照组,差异均有统计学意义(P<0.05)。治疗前,两组患者临床症状评分比较,差异无统计学意义(P>0.05)。治疗后,两组患者临床症状评分均显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:瑞巴派特三联疗法用于胃溃疡伴胃出血的近期疗效显著,可有效改善患者的消化道症状,降低再出血发生风险,且未增加不良反应的发生。

OBJECTIVE：To observe the efficacy and safety of rebamipide triple therapy in the treatment of gastric ulcer with bleeding. METHODS：130 patients with gastric ulcer with bleeding were randomly divided into control group（65 cases）and observation group（65 cases）. Control group received Omeprazole enteric-coated capsule 20 mg,orally,twice a day＋Aluminum magnesium carbonate tablet 500 mg,orally,once a day;observation group was additionally received Rebamipide tablet 0.1 g,orally,3times a day. They were treated for 12 weeks. Clinical efficacy,remission time of belching,abdominal pain,bloating,hematemesis/hematochezia,clinical symptom score before and after treatment,rebleeding and the incidence of adverse reactions in 2 groups were observed. RESULTS：The total effective rate in observation group was significantly higher than control group,remission time of symptoms and signs were significantly shorter than control group,the incidence of rebleeding was significantly lower than control group,with statistical significances（P〈0.05）. Before treatment,there was no significant difference in the clinical symptom score（P〉0.05）. After treatment,the clinical symptom scores in 2 groups were significantly lower than before,and observation group was lower than control group,with statistical significances（P〈0.05）. And there was no significant difference in the incidence of adverse reactions（P〉0.05）. CONCLUSIONS：Rebamipide triple therapy shows obvious short-term efficacy in the treatment of gastric ulcer with bleeding,which can effectively improve patients＇ gastrointestinal symptoms,reduce rebleeding risk,and does not increase the incidence of adverse reactions.